Korro Bio, Inc.

NASDAQ:KRRO

Biotechnology

Healthcare
$12.44 +15.88%

+$1.76 today

Market cap
$170.75M
Beta
2.10
P/E (TTM)
-1.3
EPS (TTM)
-$9.79
52W Low $5.20High $55.89

Volume 0.16M

Average 0.15M

KRRO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Korro Bio, Inc.NASDAQ: KRRO

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $12.95M fell 34.4% year over year, behind the -15.8% change in trailing-twelve-month research & development. Sequentially, it rose 17.9% from the prior quarter. Over 3 fiscal years it compounded at +15.8% a year.

Context

  • Research & development amounted to 1025.9% of revenue in FY2025, down 1776.2 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -34.4% toward the trailing-twelve-month pace of -15.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.95M+17.9% QoQ
Last fiscal yearDec 2025
$65.58M+3.0% YoY
LTMMar 2026
$58.79M-15.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-34.4%——
1 year+3.0%——
3-year CAGR+15.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
65.58M USD
Year-over-year change
+3.0%
4-year CAGR
+2.5%

Research & Development vs competitors

How KRRO compares with its peers on the latest reported figures

  • KRRO's LTM Mar 2026 research & development of $58.79M is the 8th highest of the 11 companies compared; the peer median is $80.85M.
  • Its year-over-year change of -15.8% is the lowest of 9, against a peer median of +19.1%.
  • Research & development amounts to 1530.1% of revenue for KRRO, versus a peer median of 6710.8%.
KRRO Competitors Peer median
Research & Development for KRRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANNXAnnexon, Inc.LTM Mar 2026$172.31M +17.5%+18.0%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$152.7M +75.7%+85.3%—
DBVTDBV Technologies S.A.LTM Mar 2026$124.71M +42.2%+15.6%—
ENGNenGene Holdings Inc.LTM Apr 2026$98.75M +56.7%+82.8%—
AURAAura Biosciences, Inc.LTM Mar 2026$94.92M +19.3%+28.8%—
ALTAltimmune, Inc.LTM Mar 2026$66.77M -12.8%-2.0%185483.3%
SLNSilence Therapeutics plcLTM Mar 2026$61.84M —+24.0%6710.8%
KRROKorro Bio, Inc.LTM Mar 2026$58.79M -15.8%+15.8%1530.1%
ANROAlto Neuroscience, Inc.LTM Mar 2026$55.94M +19.0%+24.4%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$28.47M —+131.7%—
AMRNAmarin Corporation plcLTM Mar 2026$18.45M -6.9%-13.3%8.6%
Peer median (excluding KRRO) $80.85M+19.1%+24.2%6710.8%

Competitors are the stored peer set for KRRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue14.07M002.27M6.39M
Cost of Revenue3.84M0004.28M
Gross Profit10.23M002.27M2.11M
Gross Margin72.7%——100.0%33.0%
Research & Development59.32M42.2M57.25M63.64M65.58M
Selling, General & Admin34.93M16.8M36.54M30.55M28.16M
Operating Expenses94.26M59M84.53M94.18M89.45M
Depreciation & Amortization3.84M2.51M3.63M3.57M4.28M
EBITDA(80.07M)(56.49M)(80.9M)(88.35M)(83.06M)
EBITDA Margin-569.1%——-3890.1%-1299.5%
Operating Income(84.03M)(59M)(84.53M)(91.91M)(87.34M)
Operating Margin-597.3%——-4047.1%-1366.4%
Interest Income397K947K000
Interest Expense764K118K000
Other Income / Expenses(640K)976K3.39M8.47M(29.28M)
Income Before Tax(84.67M)(58.02M)(81.15M)(83.44M)(116.62M)
Pre-Tax Margin-601.9%——-3674.2%-1824.5%
Income Tax Expense15K10K27K141K637K
Net Income(84.69M)(58.03M)(81.17M)(83.58M)(117.26M)
Net Margin-602.0%——-3680.4%-1834.5%
EPS (Basic)(4.94)(227.58)(53.09)(9.37)(12.48)
EPS (Diluted)(4.94)(227.42)(53.08)(9.37)(12.48)
Weighted Avg Shares4.45M255K1.53M8.92M9.4M
Weighted Avg Shares (Diluted)4.45M255.17K1.53M8.92M9.4M

Korro Bio, Inc.

NASDAQ:KRRO

Intrinsic Alpha fair value

Locked

Current Price

$12.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.